EGFR and breast carcinoma: Although several mechanisms have been discovered by which Gβγ activates ERK1/2, the transactivation of EGFR pathway appears to be widely explored and accepted [43, 46–48]; the same has been demonstrated for GPER in breast cancer cells [25, 41, 42].